Category: Keratoconus

Epi-off corneal collagen cross-linking (CXL) treatment treats progressive keratoconus and ectasia that develops after refractive surgery. The procedure received FDA approval in 2016. Dr. Greenstein and his colleagues conducted a study to determine how well the procedure faired over the years. The study concluded that the treatment appears to remain stable for the majority of […]

On. August 18, 2021, Dr. Greenstein lectured to over 500 doctors on Corneal Inlays: “Past, Present, Future”

Steven A. Greenstein, MD https://www.healio.com/news/ophthalmology/20210111/corneal-tissue-addition-for-keratoconus-may-improve-visual-acuity-topography

The importance of early diagnosis of Keratoconus Peter S. Hersh MDCLEI Center for Keratoconus Dr. Hersh recently commented on an article that looked at referrals for newly diagnosed Keratoconus patients. This study of around 400 patients found that patients are first being diagnosed fairly late in the disease progression. This is important because, given the […]

A new treatment for keratoconus, called corneal collagen crosslinking (CXL), was approved by the U.S. Food and Drug Administration on April 18, 2016. The approval was granted to Avedro, Inc. for Photrexa Viscous, Photrexa and the KXL System. Collagen crosslinking uses a combination of riboflavin (a form of vitamin B2) and ultraviolet light. When use […]

At the CLEI Center for Keratoconus, Dr. Hersh and his staff are involved in a number of educational programs for keratoconus doctors and patients. In the Fall of 2012, we will sponsor our 8th Annual Keratoconus Patient Symposium in association with the National Keratoconus Foundation. In a very successful program last year, nearly 150 keratoconus […]